ClinicalTrials.gg
RecruitingNCT06554288TRIKE2Updated Jun 24, 2026

Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy

A Phase 1 interventional study of Trihexyphenidyl in Pediatric Disorder, Genetic Predisposition and Dystonia, Secondary, sponsored by Children's Mercy Hospital Kansas City. Recruiting at 1 site in United States. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Children's Mercy Hospital Kansas City · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 87 studies in Genetic Predisposition to Disease with a site in United States — 37 open to participants now, 46 under way, none of them phase 3. Genetic Predisposition to Disease · United States.

Planned enrollment
32nd of 37
40 · median 225
Started
2024
with 6 others
Phase 1
4 of 87
3 open now
Primary completion
2029-11
later than 31 of 45 live
Registered
73rd of 87
by date

Among the 87 studies in Genetic Predisposition to Disease with a site in United States, this one is the 32nd largest by planned enrollment of the 37 interventional ones that give a count, is one of 7 that started in 2024, is one of 4 in phase 1, reaches primary completion later than 31 of the 45 other live ones, and was the 73rd registered.

Genetic Predisposition to Disease

242 studies on the registry are indexed under Genetic Predisposition to Disease; 96 are open to participants now.

Browse Genetic Predisposition to Disease studies →

Open to participants now

37 of the 87 studies in Genetic Predisposition to Disease with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 71 Genetic Predisposition to Disease studies recruiting now, 36 (51%) set no upper age limit and 28 (39%) stop at 75 or younger; 25 take children under 18; 23 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Genetic Predisposition to Disease with a site in United States, or all of them as a file.
02

Study summary

This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.

Read the detailed description

This is a 16-week single-arm nonrandomized pilot study of trihexyphenidyl in children with dystonic cerebral palsy (DCP) to 1) evaluate the pharmacokinetics (PK) of trihexyphenidyl (THP) and variation in PK parameters between CYP2D6 and CYP2C19 genotypes and 2) evaluate the feasibility of a future exposure-controlled clinical trial of THP.

03

Conditions studied

  • Pediatric Disorder
  • Genetic Predisposition
  • Dystonia, Secondary
  • Dystonia
  • Cerebral Palsy, Dystonic-Rigid
  • Cerebral Palsy, Dyskinetic
  • Trihexyphenidyl Adverse Reaction
  • Pharmacogenomic Drug Interaction

Keywords

  • Pediatric
  • Cerebral Palsy
  • Dystonia
  • Pharmacogenomics
  • Trihexyphenidyl
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 5-17 years of age
  • Diagnosis of cerebral palsy and dystonia causing interference
  • Parent/legal guardian of a child with a diagnosis of cerebral palsy and dystonia
  • Parent/legal guardian is willing and able to provide informed permission/assent for the study

Exclusion criteria

Exclusion Criteria:

  • Previously or currently taking trihexyphenidyl
  • Patients turning 18 years of age within the study period (16 weeks from Study Day 1)
  • A language barrier for the patient that precludes communication and/or the ability to complete study-related requirements
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Trihexyphenidyl

    Participants receive trihexyphenidyl following the dose escalation schedule below: Week 1: 0.05 mg/kg BID Week 2: 0.05 mg/kg TID Week 3: 0.1 mg/kg TID Week 4: 0.15 mg/kg TID Week 5: 0.20 mg/kg TID Week 6-15: 0.25 mg/kg TID

    Drug: Trihexyphenidyl

Interventions

  • 6-week dose escalation up to 0.25mg/kg TID, followed by a 9-week maintenance period at this dose

06

What researchers measure

Primary outcomes

  1. Difference in Cmax between CYP2D6 and CYP2C19 phenotype groups

    Cmax will be measured in first-dose pharmacokinetic study on study day 1

    Time frame: Baseline

  2. Difference in AUC0-n between CYP2D6 and CYP2C19 phenotype groups

    AUC0-n will be measured in first-dose pharmacokinetic study on study day 1

    Time frame: Baseline

  3. Difference in AUC0-∞ between CYP2D6 and CYP2C19 phenotype groups

    AUC0-∞ will be measured in first-dose pharmacokinetic study on study day 1

    Time frame: Baseline

  4. Recruitment percentage

    Measure percent of participants who were approached for the study that enrolled in the study

    Time frame: Through study completion, an average of 2 years

  5. Retention percentage

    Measure percent of participants enrolled who completed the study

    Time frame: Through study completion, an average of 2 years

  6. Dystonia Efficacy Measures Outcome Completion

    Measure percent of participants enrolled who were able to complete each dystonia efficacy measure (see secondary outcome measures)

    Time frame: Through study completion, an average of 2 years

Secondary outcomes

  1. Number of participants with at least one adverse event as measured by the Safety Monitoring Uniform Report Form (SMURF)

    Adverse events will only include those that are determined to be related to the study drug.

    Time frame: Through study completion, an average of 2 years

  2. Change from baseline in dystonia duration as measured by the Dyskinesia Impairment Scale, Version 2 (DIS-2) (exploratory)

    The Dyskinesia Impairment Scale, Version 2 (DIS-2) is an updated version of the Dyskinesia Impairment Scale used to assess dystonia across multiple body regions. Duration of dystonia using subscale DIS-D are measured in 12 body regions during activity and rest. Dystonia duration scores are measured on a 4-point scale from 0 to 4 with 0 being dystonia is absent and 4 being dystonia is always present (≥90%).

    Time frame: Baseline, 16 weeks

  3. Change from baseline in dystonia amplitude as measured by the Dyskinesia Impairment Scale (exploratory)

    Amplitude of dystonia using subscale DIS-D are measured in 12 body regions during activity and rest. Dystonia amplitude scores are measured on a 4-point scale from 0 to 4 with 0 being dystonia is absent and 4 being dystonia in maximal range of motion (≥90%).

    Time frame: Baseline, 16 weeks

  4. Change from baseline in dystonia as measured by the Quality of Upper Extremity Skills Test (QUEST) (exploratory)

    Upper extremity function in 1 domain; grasp. 13 activities with item-level scores and three items for the tester to rate: hand function, spasticity, and cooperativeness. All scores are summed, and formulas are used to calculate percentages for this domain. Domain percentage is summed with a minimum score less than 0, and the maximum score is 100.

    Time frame: Baseline, 16 weeks

  5. Change in functional impact from baseline as measured by the Dyskinetic Cerebral Palsy Functional Impact Scale (D-FIS) (exploratory)

    Functional impact scores are measured on a 5-point scale from 0 to 4 with 0 being dyskinesia may be present but has no impact on the named activity, and 4 being dyskinesia is present and prevents child from doing a named activity, even with help. An "NA" option indicates the activity is difficult but NOT due to dyskinesia.

    Time frame: Baseline, 16 weeks

  6. Change in priority scores in functional impact from baseline as measured by the Dyskinetic Cerebral Palsy Functional Impact Scale (D-FIS) (exploratory)

    Priority scores are measured on a 4-point scale from 1 to 4 with 1 being an activity is not a priority and 4 being an activity is highest priority.

    Time frame: Baseline, 16 weeks

  7. Change in patient-driven performance from baseline as measured by the Canadian Occupational Performance Measure (exploratory)

    Performance scores are measured on a 10-point scale with 1 being not able to do an activity at all and 10 being able to do an activity extremely well.

    Time frame: Baseline, 16 weeks

  8. Change in patient-driven goal satisfaction from baseline as measured by the Canadian Occupational Performance Measure (exploratory)

    Satisfaction scores are measured on a 10-point scale with 1 being not satisfied at all with the way they do an activity to 10 being extremely satisfied with the way they do an activity.

    Time frame: Baseline, 16 weeks

  9. Change in caregiver's perspective about their child in 4 domains: health status, comfort, wellbeing, functional abilities, and ease of caregiving from baseline as measured by Caregiver Priorities and Child Health Index of Life with Disabilities

    Scores for each domain and for the total survey are standardized and range from 0 to 100 with 0 being the worst and 100 being the best.

    Time frame: Baseline, 16 weeks

  10. Measure the acceptability of outcome measures at 16 weeks as measured by the Acceptability of Intervention Measure

    Scores are measured on a 5-point scale from Completely Disagree to Completely Agree for items 1) The outcome measure meets my approval. 2) The outcome measure is appealing to me. 3) I like the outcome measure. 4) I welcome the outcome measure

    Time frame: 16 weeks

  11. Change in disease severity from baseline as measured by the Patient Global Impression of Severity (PGI-S) (exploratory)

    The Patient Global Impression of Severity (PGI-S) is a single-item outcome measure assessing overall disease severity over the past week. Clinicians rate the participant's condition on a 5-point scale: none, mild, moderate, severe, or very severe. Higher scores indicate greater perceived severity.

    Time frame: Baseline and 16 weeks

  12. Change in overall status as measured by the Patient Global Impression of Change (PGI-C)

    The Patient Global Impression of Change (PGI-C) is a single-item outcome assessing overall change since the start of the study. Participants and the clinician rate the participant's condition on a 7-point Likert scale ranging from very much improved to very much worse.

    Time frame: Week 16

07

Study locations

1 of 1 sites recruiting
  • Children's Mercy Hospital Kansas City
    Kansas City, Missouri 64108, United States
    Recruiting
    • Rachel Nass · Contactrnass@cmh.edu · 816-601-1354
    • Rose Gelineau-Morel, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Pharmacokinetic data, including genotypes and THP levels, will be in publications for analysis replication. This will include participant genotypes and corresponding levels of THP, R-THP, and S-THP. Raw data and technical duplicates are available on request for result transparency and clinical trial design. CYP2D6 and CYP2C19 data will also be published; raw sequences go to NICHD's Data Hub (https://dash.nichd.nih.gov/), new haplotypes to PharmVar (https://www.pharmvar.org/). Recruitment, retention, and scientific methods outcomes will be published to guide future THP trials, though the study isn't powered for efficacy endpoints.

Supporting information: Study protocol, Statistical analysis plan

Time frame: The data will be made available at the time of the associated publication or at the end of the study period, whichever comes first. The datasets made available through publications in PubMed will be made available indefinitely. Sharing of raw data upon request will be accommodated for at least 10 years. Once genetic data are published or uploaded to DASH or PharmVar, they will be available indefinitely.

Access criteria: Access to raw pharmacokinetic data/samples and genetic samples will be controlled because it will only be available upon request. For DASH, a request for study data can be submitted and managed within their system.

Data sharing details ↗ · dash.nichd.nih.gov

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Nov 2029, 61 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2024
First posted
Aug 15, 2024
StartActual
Oct 15, 2024
Primary completionEst.
Nov 30, 2029
CompletionEst.
Dec 31, 2029
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06554288
Responsible party
Rose Gelineau-Morel (Principal Investigator, Children's Mercy Hospital Kansas City) — Principal investigator
First posted
Aug 15, 2024
Start date
Oct 15, 2024
Primary completion
Nov 30, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Jun 24, 2026

Study contacts

Rose Gelineau-Morel, MD
Contact
rngelineaumorel@cmh.edu
816-302-3331
Rachel Nass
Contact
rnass@cmh.edu
8166011354
Rose Gelineau-Morel, MD
principal investigator · Children's Mercy Kansas City

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trihexyphenidyl

Start the discussion